Clinical Trial Update: Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study evaluating a combination of zanubrutinib, rituximab, and venetoclax in previously untreated follicular lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Rituximab (Rituxan) (rituximab)
• Venetoclax (Venclexa) (venetoclax)
• Zanubrutinib (Brukinsa) (zanubrutinib)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Status: RECRUITING